Skip to Content
Severe eczema holding you back? Find the right treatment

amoxicillin

Generic Name: amoxicillin (am OX i sil in)
Brand Name: Moxatag, ...show all 9 brand names

What is amoxicillin?

Amoxicillin is a penicillin antibiotic that fights bacteria.

Amoxicillin is used to treat many different types of infection caused by bacteria, such as tonsillitis, bronchitis, pneumonia, gonorrhea, and infections of the ear, nose, throat, skin, or urinary tract.

Amoxicillin is also sometimes used together with another antibiotic called clarithromycin (Biaxin) to treat stomach ulcers caused by Helicobacter pylori infection. This combination is sometimes used with a stomach acid reducer called lansoprazole (Prevacid).

There are many brands and forms of amoxicillin available and not all brands are listed on this leaflet.

Amoxicillin may also be used for purposes not listed in this medication guide.

What is the most important information I should know about amoxicillin?

You should not use this medicine if you are allergic to any penicillin antibiotic.

What should I discuss with my healthcare provider before taking amoxicillin?

You should not use this medicine if you are allergic to any penicillin antibiotic, such as ampicillin, dicloxacillin, oxacillin, penicillin, or ticarcillin.

To make sure amoxicillin is safe for you, tell your doctor if you have:

  • asthma;

  • liver or kidney disease;

  • mononucleosis (also called "mono");

  • a history of diarrhea caused by taking antibiotics; or

  • food or drug allergies (especially to a cephalosporin antibiotic such as Omnicef, Cefzil, Ceftin, Keflex, and others).

If you are being treated for gonorrhea, your doctor may also have you tested for syphilis, another sexually transmitted disease.

Amoxicillin is not expected to harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant during treatment.

Amoxicillin can make birth control pills less effective. Ask your doctor about using non hormonal birth control (condom, diaphragm with spermicide) to prevent pregnancy while taking amoxicillin.

Amoxicillin can pass into breast milk and may harm a nursing baby. Tell your doctor if you are breast-feeding a baby.

The amoxicillin chewable tablet may contain phenylalanine. Talk to your doctor before using this form of amoxicillin if you have phenylketonuria (PKU).

How should I take amoxicillin?

Follow all directions on your prescription label. Do not take this medicine in larger or smaller amounts or for longer than recommended.

Take this medicine at the same time each day.

The Moxatag brand of amoxicillin should be taken with food, or within 1 hour after eating a meal.

Some forms of amoxicillin may be taken with or without food. Check your medicine label to see if you should take your amoxicillin with food or not.

You may need to shake amoxicillin liquid well just before you measure a dose. Follow the directions on your medicine label.

Measure liquid medicine with the dosing syringe provided, or with a special dose-measuring spoon or medicine cup. If you do not have a dose-measuring device, ask your pharmacist for one. You may place the liquid directly on the tongue, or you may mix it with water, milk, baby formula, fruit juice, or ginger ale. Drink all of the mixture right away. Do not save any for later use.

The chewable tablet should be chewed before you swallow it.

Do not crush, chew, or break an extended-release tablet. Swallow it whole.

While using amoxicillin, you may need frequent blood tests. Your kidney and liver function may also need to be checked.

If you are taking amoxicillin with clarithromycin and/or lansoprazole to treat stomach ulcer, use all of your medications as directed. Read the medication guide or patient instructions provided with each medication. Do not change your doses or medication schedule without your doctor's advice.

Use this medicine for the full prescribed length of time. Your symptoms may improve before the infection is completely cleared. Skipping doses may also increase your risk of further infection that is resistant to antibiotics. Amoxicillin will not treat a viral infection such as the flu or a common cold.

Do not share this medicine with another person, even if they have the same symptoms you have.

This medicine can cause unusual results with certain medical tests. Tell any doctor who treats you that you are using amoxicillin.

Store at room temperature away from moisture, heat, and light.

You may store liquid amoxicillin in a refrigerator but do not allow it to freeze. Throw away any liquid amoxicillin that is not used within 14 days after it was mixed at the pharmacy.

What happens if I miss a dose?

Take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.

What happens if I overdose?

Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

Overdose symptoms may include confusion, behavior changes, a severe skin rash, urinating less than usual, or seizure (black-out or convulsions).

What should I avoid while taking amoxicillin?

Antibiotic medicines can cause diarrhea, which may be a sign of a new infection. If you have diarrhea that is watery or bloody, stop using amoxicillin and call your doctor. Do not use anti-diarrhea medicine unless your doctor tells you to.

Amoxicillin side effects

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have:

  • diarrhea that is watery or bloody;

  • fever, swollen gums, painful mouth sores, pain when swallowing, skin sores, cold or flu symptoms, cough, trouble breathing;

  • swollen glands, rash or itching, joint pain, or general ill feeling;

  • pale or yellowed skin, yellowing of the eyes, dark colored urine, fever, confusion or weakness;

  • severe tingling, numbness, pain, muscle weakness;

  • easy bruising, unusual bleeding (nose, mouth, vagina, or rectum), purple or red pinpoint spots under your skin; or

  • severe skin reaction--fever, sore throat, swelling in your face or tongue, burning in your eyes, skin pain, followed by a red or purple skin rash that spreads (especially in the face or upper body) and causes blistering and peeling.

Common side effects may include:

  • stomach pain, nausea, vomiting, diarrhea;

  • vaginal itching or discharge;

  • headache; or

  • swollen, black, or "hairy" tongue.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Side Effects (complete list)

Amoxicillin dosing information

Usual Adult Dose for Bacterial Endocarditis Prophylaxis:

American Heart Association (AHA) recommendations:
-Immediate-release: 2 g orally as a single dose 30 to 60 minutes prior to procedure

Comments:
-Prophylaxis should be used for patients at high risk of adverse outcomes from endocarditis with underlying cardiac conditions who undergo any dental procedure that involves manipulation of gingival tissue or periapical region of a tooth and for those procedures that perforate oral mucosa.
-Prophylaxis should also be used for patients at high risk of adverse outcomes from endocarditis who undergo invasive respiratory tract procedures.
-Current guidelines should be consulted for additional information.

Usual Adult Dose for Chlamydia Infection:

US CDC recommendations: 500 mg orally 3 times a day for 7 days in pregnant patients as an alternative to azithromycin

Comments:
-Women less than 25 years and those at an increased risk for chlamydia should be re-screened during the third trimester of pregnancy to prevent maternal postnatal complications and chlamydial infection in the infant.
-Current guidelines should be consulted for additional information.

Usual Adult Dose for Helicobacter pylori Infection:

Immediate-release:
-Dual Therapy: 1 g orally every 8 hours for 14 days in combination with lansoprazole
-Triple Therapy: 1 g orally every 12 hours for 14 days in combination with clarithromycin and lansoprazole

Comments: Refer to clarithromycin and lansoprazole for full prescribing information.

Usual Adult Dose for Lyme Disease -- Arthritis:

Infectious Diseases Society of America (IDSA) recommendations: 500 mg orally 3 times a day for 14 to 28 days

Comments:
-Duration of treatment depends upon severity of condition being treated.
-Current guidelines should be consulted for additional information.

Usual Adult Dose for Lyme Disease -- Carditis:

Infectious Diseases Society of America (IDSA) recommendations: 500 mg orally 3 times a day for 14 to 28 days

Comments:
-Duration of treatment depends upon severity of condition being treated.
-Current guidelines should be consulted for additional information.

Usual Adult Dose for Lyme Disease -- Erythema Chronicum Migrans:

Infectious Diseases Society of America (IDSA) recommendations: 500 mg orally 3 times a day for 14 to 28 days

Comments:
-Duration of treatment depends upon severity of condition being treated.
-Current guidelines should be consulted for additional information.

Usual Adult Dose for Lyme Disease:

Infectious Diseases Society of America (IDSA) recommendations: 500 mg orally 3 times a day for 14 to 28 days

Comments:
-Duration of treatment depends upon severity of condition being treated.
-Current guidelines should be consulted for additional information.

Usual Adult Dose for Pneumonia:

Immediate-release:
-Mild, moderate, or severe infection: 500 mg orally every 8 hours or 875 mg every 12 hours

Use: For the treatment of infections of the lower respiratory tract due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) S pneumoniae, Staphylococcus species, and H influenzae

IDSA and American Thoracic Society (ATS) recommendations:
Pneumonia:
-Immediate-release: 1 g orally 3 times a day

Comments:
-Patients should be treated for a minimum of 5 days, be afebrile for 48 to 72 hours, and have no more than 1 community-acquired pneumonia (CAP)-associated sign of clinical instability before discontinuing therapy.
-Used in combination with other medications.
-Current guidelines should be consulted for additional information.

Use: For outpatient empirical treatment of community-acquired pneumonia

Usual Adult Dose for Bronchitis:

Immediate-release:
-Mild, moderate, or severe infection: 500 mg orally every 8 hours or 875 mg every 12 hours

Use: For the treatment of infections of the lower respiratory tract due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) S pneumoniae, Staphylococcus species, and H influenzae

IDSA and American Thoracic Society (ATS) recommendations:
Pneumonia:
-Immediate-release: 1 g orally 3 times a day

Comments:
-Patients should be treated for a minimum of 5 days, be afebrile for 48 to 72 hours, and have no more than 1 community-acquired pneumonia (CAP)-associated sign of clinical instability before discontinuing therapy.
-Used in combination with other medications.
-Current guidelines should be consulted for additional information.

Use: For outpatient empirical treatment of community-acquired pneumonia

Usual Adult Dose for Sinusitis:

Immediate-release:
-Mild to moderate infection: 250 mg orally every 8 hours or 500 mg every 12 hours
-Severe infection: 500 mg orally every 8 hours or 875 mg every 12 hours

Comments: Dosing for infections caused by bacteria that are intermediate in their susceptibility should follow recommendations for severe infections.

Uses: For the treatment of infections of the ear, nose and throat due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) Streptococcus pneumoniae, Staphylococcus species, or Haemophilus influenzae; for the treatment of infections of the genitourinary tract due to susceptible (only beta lactamase negative) isolates of Escherichia coli, Proteus mirabilis, or Enterococcus faecalis; and for the treatment of infections of the skin and structure due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) S pneumoniae, Staphylococcus species, and H influenzae

Usual Adult Dose for Urinary Tract Infection:

Immediate-release:
-Mild to moderate infection: 250 mg orally every 8 hours or 500 mg every 12 hours
-Severe infection: 500 mg orally every 8 hours or 875 mg every 12 hours

Comments: Dosing for infections caused by bacteria that are intermediate in their susceptibility should follow recommendations for severe infections.

Uses: For the treatment of infections of the ear, nose and throat due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) Streptococcus pneumoniae, Staphylococcus species, or Haemophilus influenzae; for the treatment of infections of the genitourinary tract due to susceptible (only beta lactamase negative) isolates of Escherichia coli, Proteus mirabilis, or Enterococcus faecalis; and for the treatment of infections of the skin and structure due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) S pneumoniae, Staphylococcus species, and H influenzae

Usual Adult Dose for Tonsillitis/Pharyngitis:

Extended-release: 775 mg orally once a day within 1 hour after a meal for 10 days

Comments: The full 10-day course of treatment should be completed in order to be effective.

Uses: For the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes

IDSA recommendations:
Immediate-release: 1000 mg orally once a day or 500 mg orally twice a day

Use: For the treatment of Group A Streptococcal pharyngitis

Usual Adult Dose for Skin and Structure Infection:

Immediate-release:
-Mild to moderate infection: 250 mg orally every 8 hours or 500 mg every 12 hours
-Severe infection: 500 mg orally every 8 hours or 875 mg every 12 hours

Comments: Dosing for infections caused by bacteria that are intermediate in their susceptibility should follow recommendations for severe infections.

Use: For the treatment of infections of the skin and structure due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) S pneumoniae, Staphylococcus species, and H influenzae

IDSA recommendations:
-Immediate-release: 500 mg orally 3 times a day for 7 to 10 days

Use: For the treatment of erysipeloid

Usual Adult Dose for Cutaneous Bacillus anthracis:

US CDC Recommendations: 1 g orally every 8 hours
Duration of prophylaxis: 60 days

Comments:
-Recommended as an alternative oral regimen for postexposure prophylaxis and cutaneous anthrax without systemic involvement; recommended for penicillin-susceptible strains
-Current guidelines should be consulted for additional information.

Usual Adult Dose for Anthrax Prophylaxis:

US CDC Recommendations: 1 g orally every 8 hours
Duration of prophylaxis: 60 days

Comments:
-Recommended as an alternative oral regimen for postexposure prophylaxis and cutaneous anthrax without systemic involvement; recommended for penicillin-susceptible strains
-Current guidelines should be consulted for additional information.

Usual Pediatric Dose for Bacterial Endocarditis Prophylaxis:

AHA recommendations:
Children:
-Immediate-release: 50 mg/kg orally as a single dose 30 to 60 minutes prior to procedure; maximum of 2 g/dose

Comments:
-Prophylaxis should be used for patients at high risk of adverse outcomes from endocarditis with underlying cardiac conditions who undergo any dental procedure that involves manipulation of gingival tissue or periapical region of a tooth and for those procedures that perforate oral mucosa.
-Prophylaxis should also be used for patients at high risk of adverse outcomes from endocarditis who undergo invasive respiratory tract procedures.
-Current guidelines should be consulted for additional information.

Usual Pediatric Dose for Sinusitis:

Immediate-Release Formulations:
Mild, Moderate, or Severe Infection:
3 months or younger: Up to 30 mg/kg/day orally in divided doses every 12 hours

Comments:
-Treatment should be continued for a minimum of 48 to 72 hours beyond the time the patient becomes asymptomatic or evidence of bacterial eradication occurs.
-At least 10 days of treatment for any infection caused by Streptococcus pyogenes is recommended to prevent the occurrence of acute rheumatic fever.

Immediate-Release Formulations:
Mild to Moderate Infection:
4 months or older:
-Less than 40 kg: 20 mg/kg/day orally in divided doses every 8 hours or 25 mg/kg/day in divided doses every 12 hours
-At least 40 kg: 250 mg orally every 8 hours or 500 mg every 12 hours

Severe Infection:
4 months or older:
-Less than 40 kg: 40 mg/kg/day orally in divided doses every 8 hours or 45 mg/kg/day in divided doses every 12 hours
-At least 40 kg: 500 mg orally every 8 hours or 875 mg every 12 hours

Comments: Dosing for infections caused by bacteria that are intermediate in their susceptibility should follow recommendations for severe infections.

Uses: For the treatment of infections of the ear, nose and throat due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) Streptococcus pneumoniae, Staphylococcus species, or Haemophilus influenzae; for the treatment of infections of the genitourinary tract due to susceptible (only beta lactamase negative) isolates of Escherichia coli, Proteus mirabilis, or Enterococcus faecalis; and for the treatment of infections of the skin and structure due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) S pneumoniae, Staphylococcus species, and H influenzae

Usual Pediatric Dose for Skin or Soft Tissue Infection:

Immediate-Release Formulations:
Mild, Moderate, or Severe Infection:
3 months or younger: Up to 30 mg/kg/day orally in divided doses every 12 hours

Comments:
-Treatment should be continued for a minimum of 48 to 72 hours beyond the time the patient becomes asymptomatic or evidence of bacterial eradication occurs.
-At least 10 days of treatment for any infection caused by Streptococcus pyogenes is recommended to prevent the occurrence of acute rheumatic fever.

Immediate-Release Formulations:
Mild to Moderate Infection:
4 months or older:
-Less than 40 kg: 20 mg/kg/day orally in divided doses every 8 hours or 25 mg/kg/day in divided doses every 12 hours
-At least 40 kg: 250 mg orally every 8 hours or 500 mg every 12 hours

Severe Infection:
4 months or older:
-Less than 40 kg: 40 mg/kg/day orally in divided doses every 8 hours or 45 mg/kg/day in divided doses every 12 hours
-At least 40 kg: 500 mg orally every 8 hours or 875 mg every 12 hours

Comments: Dosing for infections caused by bacteria that are intermediate in their susceptibility should follow recommendations for severe infections.

Uses: For the treatment of infections of the ear, nose and throat due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) Streptococcus pneumoniae, Staphylococcus species, or Haemophilus influenzae; for the treatment of infections of the genitourinary tract due to susceptible (only beta lactamase negative) isolates of Escherichia coli, Proteus mirabilis, or Enterococcus faecalis; and for the treatment of infections of the skin and structure due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) S pneumoniae, Staphylococcus species, and H influenzae

Usual Pediatric Dose for Urinary Tract Infection:

Immediate-Release Formulations:
Mild, Moderate, or Severe Infection:
3 months or younger: Up to 30 mg/kg/day orally in divided doses every 12 hours

Comments:
-Treatment should be continued for a minimum of 48 to 72 hours beyond the time the patient becomes asymptomatic or evidence of bacterial eradication occurs.
-At least 10 days of treatment for any infection caused by Streptococcus pyogenes is recommended to prevent the occurrence of acute rheumatic fever.

Immediate-Release Formulations:
Mild to Moderate Infection:
4 months or older:
-Less than 40 kg: 20 mg/kg/day orally in divided doses every 8 hours or 25 mg/kg/day in divided doses every 12 hours
-At least 40 kg: 250 mg orally every 8 hours or 500 mg every 12 hours

Severe Infection:
4 months or older:
-Less than 40 kg: 40 mg/kg/day orally in divided doses every 8 hours or 45 mg/kg/day in divided doses every 12 hours
-At least 40 kg: 500 mg orally every 8 hours or 875 mg every 12 hours

Comments: Dosing for infections caused by bacteria that are intermediate in their susceptibility should follow recommendations for severe infections.

Uses: For the treatment of infections of the ear, nose and throat due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) Streptococcus pneumoniae, Staphylococcus species, or Haemophilus influenzae; for the treatment of infections of the genitourinary tract due to susceptible (only beta lactamase negative) isolates of Escherichia coli, Proteus mirabilis, or Enterococcus faecalis; and for the treatment of infections of the skin and structure due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) S pneumoniae, Staphylococcus species, and H influenzae

Usual Pediatric Dose for Pneumonia:

Immediate-Release Formulations:
Mild, Moderate, or Severe infection:
3 months or younger: Up to 30 mg/kg/day orally in divided doses every 12 hours
4 months or older:
-Less than 40 kg: 40 mg/kg/day orally in divided doses every 8 hours or 45 mg/kg/day in divided doses every 12 hours
-At least 40 kg: 500 mg orally every 8 hours or 875 mg every 12 hours

Use: For the treatment of infections of the lower respiratory tract due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) S pneumoniae, Staphylococcus species, and H influenzae

IDSA and the Pediatric Infectious Diseases Society recommendations:
Immediate-release formulations:
4 months or older:
-Empiric therapy for presumed bacterial pneumonia: 90 mg/kg/day orally in 2 divided doses; maximum 4 g/day
-Streptococcus pneumoniae (penicillin minimum inhibitory concentration of 2 mcg/mL or less): 90 mg/kg/day orally in 2 divided doses or 45 mg/kg/day in 3 divided doses
-Group A Streptococcus: 50 to 75 mg/kg/day orally in 2 divided doses
-Haemophilus influenza typeable (A to F) or nontypeable: 75 to 100 mg/kg/day orally in 3 divided doses

Comments: Current guidelines should be consulted for additional information.

Use: For the management of community-acquired pneumonia

Usual Pediatric Dose for Bronchitis:

Immediate-Release Formulations:
Mild, Moderate, or Severe infection:
3 months or younger: Up to 30 mg/kg/day orally in divided doses every 12 hours
4 months or older:
-Less than 40 kg: 40 mg/kg/day orally in divided doses every 8 hours or 45 mg/kg/day in divided doses every 12 hours
-At least 40 kg: 500 mg orally every 8 hours or 875 mg every 12 hours

Use: For the treatment of infections of the lower respiratory tract due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) S pneumoniae, Staphylococcus species, and H influenzae

IDSA and the Pediatric Infectious Diseases Society recommendations:
Immediate-release formulations:
4 months or older:
-Empiric therapy for presumed bacterial pneumonia: 90 mg/kg/day orally in 2 divided doses; maximum 4 g/day
-Streptococcus pneumoniae (penicillin minimum inhibitory concentration of 2 mcg/mL or less): 90 mg/kg/day orally in 2 divided doses or 45 mg/kg/day in 3 divided doses
-Group A Streptococcus: 50 to 75 mg/kg/day orally in 2 divided doses
-Haemophilus influenza typeable (A to F) or nontypeable: 75 to 100 mg/kg/day orally in 3 divided doses

Comments: Current guidelines should be consulted for additional information.

Use: For the management of community-acquired pneumonia

Usual Pediatric Dose for Tonsillitis/Pharyngitis:

12 years or older:
-Extended-release: 775 mg orally once a day within 1 hour after a meal for 10 days

Comments: The full 10-day course of treatment should be completed in order to be effective.

Uses: For the treatment of tonsillitis and/or pharyngitis secondary to S pyogenes

IDSA recommendations:
Immediate-release: 50 mg/kg (maximum 1000 mg) orally once a day or 25 mg/kg (maximum 500 mg) twice a day

Use: For the treatment of Group A Streptococcal pharyngitis

Usual Pediatric Dose for Lyme Disease:

IDSA recommendations:
Children:
-Immediate-release: 50 mg/kg/day orally in 3 divides doses for 14 to 28 days; maximum single dose of 500 mg

Comments:
-Duration of treatment depends upon severity of condition being treated.
-Current guidelines should be consulted for additional information.

Usual Pediatric Dose for Otitis Media:

American Academy of Pediatrics (AAP) and American Academy of Family Physicians (AAFP) recommendations:
-Immediate-release: 80 to 90 mg/kg/day orally in 2 divided doses; some experts recommend 90 mg/kg orally in 2 divided doses as initial therapy

Comments:
-Optimal duration of treatment uncertain; however, for young children and children with severe disease at any age, a 10 day course is recommended; children 6 years or older with mild or moderate disease should find a duration of 5 to 7 days appropriate.
-Current guidelines should be consulted for additional information.

Use: For the treatment of acute otitis media

Usual Pediatric Dose for Inhalation Bacillus anthracis:

AAP Recommendations:
Up to 1 week of age:
-Gestational age 32 to 37 weeks: 50 mg/kg orally in divided doses every 12 hours
-Term neonate: 75 mg/kg orally in divided doses every 8 hours

1 to 4 weeks:
-Gestational age 32 to 37 weeks: 75 mg/kg orally in divided doses every 8 hours
-Term neonate: 75 mg/kg/day orally in divided doses every 8 hours

1 month or older: 75 mg/kg/day orally in divided doses every 8 hours; not to exceed 1 g/dose

Duration of Therapy:
Postexposure prophylaxis for B anthracis infection: 60 days after exposure

Cutaneous anthrax without systemic involvement:
-Bioterrorism-related cases: To complete an antimicrobial regimen of up to 60 days from onset of illness
-Naturally-acquired cases: 7 to 10 days

Follow-up for severe anthrax:
-To complete a regimen of 10 to 14 days or longer (up to 4 weeks of age) or to complete a regimen of 14 days or longer (1 month or older)
-Patients may require prophylaxis to complete an antimicrobial regimen of up to 60 days from onset of illness.

Comments:
-Recommended as an alternative regimen for postexposure prophylaxis, the treatment of cutaneous anthrax without systemic involvement, and oral follow-up therapy for severe anthrax
-Recommended as an alternative for penicillin-susceptible strains
-Recommended for use with a protein synthesis inhibitor when used for follow-up therapy for severe anthrax (includes anthrax meningitis, inhalation anthrax, injection anthrax, gastrointestinal anthrax, and cutaneous anthrax with systemic involvement, extensive edema, or lesions of the head or neck).
-Current guidelines should be consulted for additional information.

Usual Pediatric Dose for Cutaneous Bacillus anthracis:

AAP Recommendations:
Up to 1 week of age:
-Gestational age 32 to 37 weeks: 50 mg/kg orally in divided doses every 12 hours
-Term neonate: 75 mg/kg orally in divided doses every 8 hours

1 to 4 weeks:
-Gestational age 32 to 37 weeks: 75 mg/kg orally in divided doses every 8 hours
-Term neonate: 75 mg/kg/day orally in divided doses every 8 hours

1 month or older: 75 mg/kg/day orally in divided doses every 8 hours; not to exceed 1 g/dose

Duration of Therapy:
Postexposure prophylaxis for B anthracis infection: 60 days after exposure

Cutaneous anthrax without systemic involvement:
-Bioterrorism-related cases: To complete an antimicrobial regimen of up to 60 days from onset of illness
-Naturally-acquired cases: 7 to 10 days

Follow-up for severe anthrax:
-To complete a regimen of 10 to 14 days or longer (up to 4 weeks of age) or to complete a regimen of 14 days or longer (1 month or older)
-Patients may require prophylaxis to complete an antimicrobial regimen of up to 60 days from onset of illness.

Comments:
-Recommended as an alternative regimen for postexposure prophylaxis, the treatment of cutaneous anthrax without systemic involvement, and oral follow-up therapy for severe anthrax
-Recommended as an alternative for penicillin-susceptible strains
-Recommended for use with a protein synthesis inhibitor when used for follow-up therapy for severe anthrax (includes anthrax meningitis, inhalation anthrax, injection anthrax, gastrointestinal anthrax, and cutaneous anthrax with systemic involvement, extensive edema, or lesions of the head or neck).
-Current guidelines should be consulted for additional information.

Usual Pediatric Dose for Anthrax Prophylaxis:

AAP Recommendations:
Up to 1 week of age:
-Gestational age 32 to 37 weeks: 50 mg/kg orally in divided doses every 12 hours
-Term neonate: 75 mg/kg orally in divided doses every 8 hours

1 to 4 weeks:
-Gestational age 32 to 37 weeks: 75 mg/kg orally in divided doses every 8 hours
-Term neonate: 75 mg/kg/day orally in divided doses every 8 hours

1 month or older: 75 mg/kg/day orally in divided doses every 8 hours; not to exceed 1 g/dose

Duration of Therapy:
Postexposure prophylaxis for B anthracis infection: 60 days after exposure

Cutaneous anthrax without systemic involvement:
-Bioterrorism-related cases: To complete an antimicrobial regimen of up to 60 days from onset of illness
-Naturally-acquired cases: 7 to 10 days

Follow-up for severe anthrax:
-To complete a regimen of 10 to 14 days or longer (up to 4 weeks of age) or to complete a regimen of 14 days or longer (1 month or older)
-Patients may require prophylaxis to complete an antimicrobial regimen of up to 60 days from onset of illness.

Comments:
-Recommended as an alternative regimen for postexposure prophylaxis, the treatment of cutaneous anthrax without systemic involvement, and oral follow-up therapy for severe anthrax
-Recommended as an alternative for penicillin-susceptible strains
-Recommended for use with a protein synthesis inhibitor when used for follow-up therapy for severe anthrax (includes anthrax meningitis, inhalation anthrax, injection anthrax, gastrointestinal anthrax, and cutaneous anthrax with systemic involvement, extensive edema, or lesions of the head or neck).
-Current guidelines should be consulted for additional information.

What other drugs will affect amoxicillin?

Other drugs may interact with amoxicillin, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell each of your health care providers about all medicines you use now and any medicine you start or stop using.

Where can I get more information?

  • Your pharmacist can provide more information about amoxicillin.
  • Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.
  • Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 1996-2012 Cerner Multum, Inc. Version: 9.05.

Last reviewed: July 22, 2016
Date modified: December 03, 2017

Hide